This inventor holds 1 USPTO granted patent. Top assignee: Kaken Pharmaceutical Company, Ltd.. Active years: 2004.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2004
Title: Seiji Amano: Innovator in Tetrahydroquinoline Compounds
Introduction
Seiji Amano is a prominent inventor based in Kyoto, Japan. He is known for his significant contributions to the field of pharmacology, particularly through his innovative work on tetrahydroquinoline compounds. His research focuses on developing compounds that exhibit therapeutic effects on androgen receptor-mediated diseases.
Latest Patents
Amano holds a patent for tetrahydroquinoline compounds, which are characterized by a specific and strong binding affinity for androgen receptors (AR). These compounds can act as either AR agonists or antagonists, providing therapeutic benefits without excessive action on the prostate. Instead, they demonstrate potent effects on skeletal muscle and bone tissue. This patent represents a significant advancement in the treatment of AR-mediated diseases.
Career Highlights
Seiji Amano is affiliated with Kaken Pharmaceutical Company, Ltd., where he continues to contribute to pharmaceutical research and development. His work has garnered attention for its potential to improve treatment options for various medical conditions.
Collaborations
Amano collaborates with notable colleagues, including Motonori Miyakawa and Misa Kamei. Their combined expertise enhances the research and development efforts at Kaken Pharmaceutical Company.
Conclusion
Seiji Amano's innovative work in the field of tetrahydroquinoline compounds showcases his dedication to advancing medical science. His contributions have the potential to significantly impact the treatment of AR-mediated diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile